NorthWest Biotherapeutics Inc (NWBO)

[GermanCol]

Bio, I agree with your argument about the very small percentage of the remaining control arm as part of the total trial and think that it may even be smaller than 10%.

The reason why I think that is possible is because there are 18 patients that were part of the original placebo group but were not counted in the events of the PFS chart (these patients should correspond to censors specifically for PFS analysis, but not for OS analysis I think):

99 (original placebo group) - 81 (PFS events) =18

And also, there are 17 patients that had their progression event counted but were not included in the 64 patients corresponding to the recurrent GBM arm:

81 (PFS events) - 64 (rGBM arm patients) = 17

.

I think it is possible that part of those two groups of patients received DCVax, but were not real progressors (they could have been pseudoprogressors from SOC) or didn't classify to be part of the rGBM arm. If that is the case, they could have done well in terms of OS because of DCVax but don't be part of any of the nGBM or rGBM arms. That's why I think final trial results are going to be even better than what we have seen until now.